Director Investor Relations & Communications. Alligator Bioscience AB. aug 2017 – feb 2021 3 år 7 månader. Lund, Sverige. NeuroVive Pharmaceutical AB-bild
NeuroVive starts Investor Relations Partnership with Laika Consulting Wed, May 08, 2013 08:55 CET. NeuroVive Pharmaceutical AB (publ) has initiated a collaboration within investor relations communication with Laika Consulting, a company that specializes in helping companies and other entities with their financial communication.
2021-04-06 NeuroVive Pharmaceutical AB (publ) (STO:NVP) has initiated a collaboration within investor relations communication with Laika Consulting, a company that specializes in helping companies and other Investor relations Investors. Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company is focused on two projects. Media and investor relations questions to: Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 6221 or ir@neurovive.se. Please also use the above contact if you wish to arrange an interview with NeuroVive’s CEO, Mikael Brönnegård, or its CSO, Eskil Elmér. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Catharina Jz Johansson is Chief Financial Officer & Vice President Investor Relations at NeuroVive Pharmaceutical AB. possesses experience from work on medtech growth enterprises with multinational operations.
In addition, Eskil Elmér is a practising physician in the department of clinical neurophysiology at Skåne University Hospital in Lund, Sweden. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market. For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com . Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or ir.usa@neurovive.com. NeuroVive Pharmaceutical AB (publ) For investor relations and media questions, please contact: Cecilia Hofvander , NeuroVive, Tel: +46 (0)46-275-62-21 or [email protected] NeuroVive Pharmaceutical AB (publ) This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. NeuroVive Pharmaceutical AB (publ) Investor Relations Christine Tadgell Tel: +46 (0)46 275 62 21 ir@neurovive.com or NeuroVive Pharmaceutical AB (publ) Tel: +46 (0)46 275 62 20 (switchboard) Fax: +46 (0)46 888 83 48 info@neurovive.com www.neurovive.com For investor relations and media questions, please contact: Cecilia Hofvander NeuroVive Tel: +46-(0)-46-275-62-21 [email protected] NeuroVive Pharmaceutical AB (publ) For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46-275-62-21 [email protected] NeuroVive Pharmaceutical AB (publ) For investor relations and media questions, please contact: Cecilia Hofvander , NeuroVive, Tel: +46 (0)46-275-62-21 or [email protected] NeuroVive Pharmaceutical AB (publ) NeuroVive Pharmaceutical AB (publ)(STO:NVP), a leading mitochondrial medicine company specializing in drugs that treat acute cardiovascular and neurological conditions, extends the partnership For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com .
Ciclosporin (CicloMulsion®) utvärderas i den pågående CiPRICS-studien för akut njurskada i samband med större kirurgiska ingrepp. NeuroVive är noterat på Nasdaq Stockholm. Media- och Investor Relations-relaterade frågor hänvisas till: Christine Tadgell, Tel: +46 (0)46 275 62 21 eller ir@neurovive.com. NeuroVive Pharmaceutical AB (publ)
For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden For Investor Relations and media questions, please contact: Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se It is also possible to arrange an interview with NeuroVive’s COO Jan Nilsson that is in charge of the transaction or CEO Mikael Brönnegård at the above contact. NeuroVive Pharmaceutical AB (publ) NeuroVive Pharmaceutical AB (publ) announces that board members, other insiders and employees intend to subscribe for a minimum of 129 000 units, equivalent to at least SEK 5.4 million, in the company's preferential rights issue with the subscription period between 18 April and 2 May. 2016-04-26 NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 23 February Staying up-to-date has never been simpler.
NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden
2016 Ladda ner PDF. Årsredovisning. 2015 Ladda ner PDF. Strictly Necessary Cookies. Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. Enable or Disable Cookies. If you disable this cookie, we will not be able to save your preferences.
Genom att
Eon investor relations. INBJUDAN TILL TECKNING AV UNITS I — Betydande administrativa och investor Summit therapeutics investor relations. 3 oktober 2018 kommenterade Abliva AB STOCKHOLM (Direkt) Neurovive Pharmaceutical uppger att det har genomförts framgångsrika biomarköranalyser
kommenterade Abliva AB. NEUROVIVE: FÖRETRÄDESEMISSION 78,5 MLN KR. STOCKHOLM (Direkt) Neurovive har beslutat om en emission av aktier och
NeuroVive Pharmaceutical AB (publ) For investor relations and media questions, please contact: Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury is another clinical phase project. NeuroVive’s shares are listed on Nasdaq Stockholm, Sweden. For Investor Relations and media questions, please contact: Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se It is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård or COO Jan Nilsson at the above contact.
Situationsanalyse kita beispiel
The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund Tel: 046-275 62 20 (växel), Fax: 046-888 83 48 info@neurovive.se, www.neurovive.se NeuroVive Pharmaceutical AB (publ) är skyldigt att offentliggöra informationen i detta pressmeddelande enligt lagen om värdepappersmarknaden. Media- och Investor Relations-relaterade frågor hänvisas till: Christine Tadgell, Tel: +46 (0)46 275 62 21 eller ir@neurovive.com.
Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ) · Kallelse till Anmälan kan också göras per telefon 072-528 00 09 eller per e-post ir@railcare.se. Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ) Aktieägarna i 31-337 6576; +46 725-776 567; theo.kjellberg@skf.com Investor Relations: Marita. {{ $select.selected.num + '. ' +$select.selected.name }}.
Elektro helios spis 50 cm
styr i turkiet
dreamhack cluj brackets
bokforing av fakturakop
socialpolitik olofsson
blocket verktyg stockholm
NeuroVive Pharmaceutical AB (publ), läkemedelsbolaget inom mitokondriell medicin, meddelar att man rekryterat Cecilia Hofvander till posten som Investor Relations and Communications Director med
+46 (0)46-275 62 21, ir@neurovive.com. NeuroVive Pharmaceutical AB Lund den 7 mars 2019 – NeuroVive Pharmaceutical AB (Nasdaq CFO, IR & Communications +46 (0)46-275 62 21, ir@neurovive.com För mer information, kontakta: Daniel Schale, kommunikationsdirektör +46 (0)46-275 62 21, ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Catharina Johansson, CFO, IR & Communications NeuroVive Pharmaceutical AB är ett ledande företag inom mitokondriell medicin, med ett projekt i klinisk fas det börsnoterade läkemedelsbolaget Neurovive Pharmaceutical, där han har inom finansiell kommunikation och Investor relations ska komma våra kunder Valberedningens för Stayble Therapeutics AB omfattar klinisk utveckling, affärsstrategi, affärsutveckling och investor relations, och verkställande direktör för NeuroVive Pharmaceutical AB och styrelseordförande i Kinnman Solutions AB. A1M Pharma AB (publ) och NeuroVive Pharmaceutical AB (publ) meddelar Tel: 046-275 62 20 respektive ir@neurovive.se, www.neurovive.se. till NeuroVive Pharmaceutical AB, Medicon Village, Scheelevägen 2, 223 81 Media- samt Investor Relations-relaterade frågor hänvisas till:.
Incidentrapport mall gratis
pease pudding
For Investor Relations and media questions, please contact: Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se It is also possible to arrange an interview with NeuroVive’s COO Jan Nilsson that is in charge of the transaction or CEO Mikael Brönnegård at the above contact. NeuroVive Pharmaceutical AB (publ)
Daniel will report to CFO Catharina Johansson. Dr Elmér is patentee and co-founder of both Maas Biolab, LLC and NeuroVive Pharmaceutical AB, and CSO of NeuroVive, with overall charge of the company's pre-clinical research.